CD274 and neoplasm: The INHBs in the subgroups for the health benefit varied from 0.06 (range: 0.14 to 0.23, probabilities of cost-effectiveness: 62%) in patients with squamous tumors to 0.57 (range: 0.16 to 0.9, probabilities of cost-effectiveness: 100%) in cancer with PD-L1 <1% and tumor mutational burden ≥10 mut/Mb.